These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12913401)

  • 41. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
    Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD
    J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IIb's are not IIb's.
    Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
    Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
    Gurbel PA; Serebruany VL; Shustov AR; Bahr RD; Carpo C; Ohman EM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1466-73. PubMed ID: 9626821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. P-selectin expression on platelets determines size and stability of platelet aggregates.
    Merten M; Thiagarajan P
    Circulation; 2000 Oct; 102(16):1931-6. PubMed ID: 11034941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
    Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
    JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thromb Haemost; 2005 Jul; 94(1):115-22. PubMed ID: 16113794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review.
    Truong KM; Amankwa K; Kucukarslan S
    Clin Ther; 2001 Aug; 23(8):1145-65; discussion 1129. PubMed ID: 11558855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M
    Acta Pol Pharm; 2009; 66(3):235-42. PubMed ID: 19645323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
    Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
    J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
    Akkerhuis KM; Maas AC; Klootwijk PA; Krucoff MW; Meij S; Califf RM; Simoons ML
    J Electrocardiol; 2000 Apr; 33(2):127-36. PubMed ID: 10819406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors.
    Rasty S; Borzak S; Tisdale JE
    J Clin Pharmacol; 2002 Dec; 42(12):1366-73. PubMed ID: 12463732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
    Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
    N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Goa KL; Noble S
    Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro effects of the glycoprotein IIb/IIIa receptor antagonists abciximab and eptifibatide on platelet aggregation in healthy cats.
    Magee AN; Hogan DF; Sederquist KA; Durham JA
    Am J Vet Res; 2014 Mar; 75(3):309-12. PubMed ID: 24564318
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
    Roe MT; Harrington RA; Prosper DM; Pieper KS; Bhatt DL; Lincoff AM; Simoons ML; Akkerhuis M; Ohman EM; Kitt MM; Vahanian A; Ruzyllo W; Karsch K; Califf RM; Topol EJ
    Circulation; 2000 Sep; 102(10):1101-6. PubMed ID: 10973837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.